Adocia (Adocia) FCF Margin % : -322.11% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Adocia FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Adocia's Free Cash Flow for the six months ended in Dec. 2023 was $-1.84 Mil. Adocia's Revenue for the six months ended in Dec. 2023 was $0.57 Mil. Therefore, Adocia's FCF Margin % for the quarter that ended in Dec. 2023 was -322.11%.

As of today, Adocia's current FCF Yield % is -4.14%.

The historical rank and industry rank for Adocia's FCF Margin % or its related term are showing as below:

ADOIF' s FCF Margin % Range Over the Past 10 Years
Min: -2622.95 Med: -128.34 Max: 4284.09
Current: -237.68

During the past 13 years, the highest FCF Margin % of Adocia was 4284.09%. The lowest was -2622.95%. And the median was -128.34%.

ADOIF's FCF Margin % is ranked worse than
56.6% of 1046 companies
in the Biotechnology industry
Industry Median: -145.305 vs ADOIF: -237.68

Adocia FCF Margin % Historical Data

The historical data trend for Adocia's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adocia FCF Margin % Chart

Adocia Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-544.77

-2,623.17

-1,356.68

-132.34

-237.44

Adocia Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-1,209.94	-94.85	-199.56	-210.38	-322.11

Competitive Comparison of Adocia's FCF Margin %

For the Biotechnology subindustry, Adocia's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adocia's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adocia's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Adocia's FCF Margin % falls into.

Adocia FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Adocia's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-5.568	/	2.345
	=	-237.44 %

Adocia's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.836	/	0.57
	=	-322.11 %

Adocia FCF Margin % Related Terms

Thank you for viewing the detailed overview of Adocia's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adocia (Adocia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adocia (OTCPK:ADOIF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ADOC:France A89:Germany

Address

115 Avenue Lacassagne, Lyon, FRA, 69003

Website

https://www.adocia.com

Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.